Anemia, Sickle Cell Clinical Trial
Official title:
A Mindfulness-based Intervention For Pain Catastrophizing In Sickle Cell Disease
Verified date | April 2017 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Significance: The purpose of this exploratory study is to test the feasibility,
accessibility, and effects of a mindfulness-based stress reduction program (MBSR) on reducing
pain catastrophizing in persons with sickle cell disease (SCD) and chronic pain. One of the
most difficult symptoms for SCD patients to manage is chronic pain. Approximately one-third
of SCD patients experience chronic pain, which is associated with pain catastrophizing. Pain
catastrophizing is a negative mental state toward pain stimuli and pain experience, and is
associated with increased pain severity, pain interference, and lower social functioning,
physical functioning, and mental health. There have been no psychobehavioral intervention
studies that have attempted to alter the experience of pain catastrophizing in persons with
SCD. MBSR is a complementary group-based therapy that emphasizes nonjudgmental awareness of
thoughts, feelings, and bodily sensations. With no pharmacological or non-pharmacological
treatment for catastrophizing in persons with SCD, MBSR offers a potential solution to this
highly significant problem for both SCD patients and providers. This project will be the
first randomized controlled trial (RCT) of MBSR to reduce pain catastrophizing, and improve
quality of life for SCD patients with chronic pain.
Methods: This study will enroll 60 adult patients with SCD and chronic pain from the Duke
Adult Sickle Cell Clinic. Patients will be randomized to a MBSR or wait-listed control group.
The MBSR group will complete a 6- week, group-based telephonic MBSR program that is
administered by a certified MBSR clinician once a week for 90 minutes. MBSR feasibility,
acceptability, and effects on pain catastrophizing will be assessed by questionnaires at
baseline, week 1, 3, and 6 in both groups. At the end of week 6, 10 randomly selected MBSR
participants will complete semi-scripted telephone interviews to help assess intervention
acceptability, and the wait-listed control condition will be offered the same MBSR
intervention.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Provide written informed consent, 2. Are >age 21, 3. Self-identify (to the PI at baseline assessment) that they are experiencing chronic, non-cancer pain that has persisted on most days for more than 6 months, and adversely affects their function or well-being, 4. are able to speak and read English, 5. Have access to a telephone (or cell phone) in the home for the intervention and individual assessment interviews (data from the SCD clinic indicate 82% of patients have a cell phone), 6. Have access to a CD or mp3 player for homework assignments and daily practice, 7. Are available during the scheduled telephone intervention, and 8. Complete and return the baseline assessment Exclusion Criteria: - Patients will be excluded if they report previously studying MBSR, currently receiving mindfulness-based or cognitive behavioral therapies, or being regular practitioners of mindfulness, including yoga. |
Country | Name | City | State |
---|---|---|---|
United States | Duke University School of Nursing | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Institute of Nursing Research (NINR), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptability of MBSR as measured by semi-scripted telephone assessments | Acceptability of the intervention will be assessed by semi-scripted telephone or in-person interviews. The semi-scripted interview will focus on MBSR patients' reflections and expectations of the program, the mindfulness skills they found useful and in what ways, the skills they found less useful and or difficult to implement, and on any changes in thoughts or actions that resulted from the application of the MBSR techniques. | 6 weeks | |
Primary | Feasibility of MBSR as measured by recruitment, attrition rates, and practice logs | Feasibility of the intervention will be assessed by recruitment and attrition rates, number of daily mindfulness logs completed, and average number of weekly minutes of mindfulness practice as recorded in logs. Feasibility data will be obtained for both the intervention and control subjects who elect to receive the intervention after the intervention is complete with the MBSR group. However, data will not be analyzed together because the delay to receiving the intervention would affect the results. Data from the control group will be used to help inform future studies. | 6 weeks | |
Secondary | Change in Pain Catastrophizing as measured by the Pain Catastrophizing Scale | Descriptive statistics will be used to summarize the pain catastrophizing at week1, 3, and 6, as measured by the Pain Catastrophizing Scale. Trajectory analyses, using a type of mixed effects model known as a random coefficients regression model for repeated measurement, will be conducted to evaluate and compare the rate and pattern of change over the 6 weeks in the MBSR and wait-listed control groups for pain catastrophizing. | baseline, week 1, week 3, and week 6 | |
Secondary | Change in Mindfulness as measured by the Mindful Attention Awareness Scale | Descriptive statistics will be used to summarize mindfulness at week1, 3, and 6, as measured by the Mindful Attention Awareness Scale. Trajectory analyses, using a type of mixed effects model known as a random coefficients regression model for repeated measurement, will be conducted to evaluate and compare the rate and pattern of change over the 6 weeks in the MBSR and wait-listed control groups for pain catastrophizing. | baseline, week 1, week 3, and week 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06078696 -
Siplizumab for Sickle Cell Disease Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02561312 -
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
|
||
Completed |
NCT00890396 -
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
|
||
Completed |
NCT00059293 -
Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
|
||
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Completed |
NCT00005277 -
Cooperative Study of The Clinical Course of Sickle Cell Disease
|
N/A | |
Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A | |
Recruiting |
NCT02286154 -
Therapeutic Response Evaluation and Adherence Trial (TREAT)
|
N/A | |
Completed |
NCT02857023 -
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
|
N/A | |
Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
Terminated |
NCT00122980 -
Stroke With Transfusions Changing to Hydroxyurea
|
Phase 3 | |
Completed |
NCT00246077 -
Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport
|
N/A | |
Completed |
NCT00094887 -
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
|
Phase 2 | |
Completed |
NCT00035763 -
Pain in Sickle Cell Epidemiologic Study
|
N/A | |
Terminated |
NCT04091737 -
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT00005300 -
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
|
N/A | |
Recruiting |
NCT04351698 -
SMILES: Study of Montelukast in Sickle Cell Disease
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06290401 -
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
|
Phase 2 |